Last checked at 21 May 2021 07:00
21 May 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Change of Nominated Adviser
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the appointment of Stifel Nicolaus Europe Limited as Nominated Advisor and Sole Corporate Broker with immediate effect.
Enquiries:
Diaceutics PLC Peter Keeling, Chief Executive Officer Philip White, Chief Financial Officer
| www.diaceutics.com via Alma PR |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison Stewart Wallace Nick Adams
| +44 (0)20 7710 7600 |
Alma PR Caroline Forde Robyn Fisher Kieran Breheny | +44 (0)20 3405 0205 or diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.